Evidence map›Paper›PMID 29773600›Full record

ArticleHaematologica2018

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34

Rajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, Amber Gordon, Donna Bucci, David M Lucas and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Multi-targeted immunotherapeutics to treat B cell malignancies.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Rajeswaran ManiComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Swagata GoswamiComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Bhavani GopalakrishnanComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Rahul RamaswamyComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Ronni WasmuthComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Minh TranComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Xiaokui MoCenter for Biostatistics, The Ohio State University, Columbus, OH, USA.
Amber GordonComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Donna BucciComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
David M LucasComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Alice MimsDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.
Christopher BrooksStemline Therapeutics, Inc., New York, NY, USA.
Adrienne DorranceComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Alison WalkerComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
William BlumComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
John C ByrdComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Gerard LozanskiComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Sumithira VasuComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Natarajan MuthusamyComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA raj.muthusamy@osumc.edu.
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Targeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6M
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemiaR01CA197844 · NCI · OHIO STATE UNIVERSITY · PI MUTHUSAMY, NATARAJAN, PHELPS, MITCH A · 2015 to 2019
$2.2M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA197844NCI NIH HHS R35 CA197734
6 · The paper itself

Abstract

Diseases with clonal hematopoiesis such as myelodysplastic syndrome and acute myeloid leukemia have high rates of relapse. Only a small subset of acute myeloid leukemia patients are cured with chemotherapy alone. Relapse in these diseases occurs at least in part due to the failure to eradicate leukemic stem cells or hematopoietic stem cells in myelodysplastic syndrome. CD123, the alpha chain of the interleukin-3 receptor heterodimer, is expressed on the majority of leukemic stem cells and myelodysplastic syndrome hematopoietic stem cells and in 80% of acute myeloid leukemia. Here, we report indiscriminate killing of CD123

Indexed as

AnimalsCD4-Positive T-LymphocytesCell Line, TumorHeterograftsHumansInterleukin-3 Receptor alpha SubunitLeukemia, Myeloid, AcuteMiceMyelodysplastic SyndromesRecombinant Fusion ProteinsTumor Cells, CulturedInterleukin-3 Receptor alpha SubunitRecombinant Fusion Proteinstagraxofusp

Identifiers

PMID29773600
PMCPMC6068035
OpenAlexW2804924284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.